danДоклады Национальной академии наук БеларусиDoklady of the National Academy of Sciences of Belarus1561-83232524-2431The Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"dan-464Research ArticleМЕДИЦИНАMEDICINEОТДАЛЕННЫЕ РЕЗУЛЬТАТЫ РАДИКАЛЬНОЙ ПРОСТАТЭКТОМИИ И АДЪЮВАНТНОЙ ЛУЧЕВОЙ ТЕРАПИИ У ПАЦИЕНТОВ, СТРАДАЮЩИХ МЕСТНО-РАСПРОСТРАНЕННЫМ РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫLONG-TERM RESULTS OF RADICAL PROSTATECTOMY AND ADJUVANT RADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCERКрасныйС. А.KrasnyS. A.

член-корреспондент, д-р мед. наук, профессор, заместитель директора

а/г Лесной, 223040, Минский р-н, Минская обл.

Corresponding Member, D. Sc. (Medicine), Professor, Deputy Director

Lesnoy, 223040, Minsk district, Minsk region

sergeykrasny@tut.byДемешкоП. Д.DemeshkoP. D.

д-р мед. наук, заведу- ющий отделом

а/г Лесной, 223040, Минский р-н, Минская обл.

D. Sc. (Medicine), Head of the Department

Lesnoy, 223040, Minsk district, Minsk region

pdemeshko@icloud.comПоляковС. Л.PolyakovS. L.

канд. мед. наук, заведующий лабораторией

а/г Лесной, 223040, Минский р-н, Минская обл.

Ph. D. (Medicine), Head of the Department

Lesnoy, 223040, Minsk district, Minsk region

s.polyakov@yahoo.comСтепановичЕ. А.StepanovichE. A.

врач-радиационный онколог

а/г Лесной, 223040, Минский р-н, Минская обл.

Radiation Oncologist

Lesnoy, 223040, Minsk district, Minsk region

Lstepanovich@tut.byМиничА. А.MinichA. A.

канд. мед. наук, вед. науч. сотрудник

а/г Лесной, 223040, Минский р-н, Минская обл.

Ph. D. (Medicine), Leading researcher

Lesnoy, 223040, Minsk district, Minsk region, 

alexander.minich@gmail.comРеспубликанский научно-практический центр онкологии и медицинской радиологии им. Н. Н. Александрова, МинскN. N. Alexandrov National Cancer Centre of Belarus, Minsk201717122017615109114Copyright © Красный С.А., Демешко П.Д., Поляков С.Л., Степанович Е.А., Минич А.А., 20172017Красный С.А., Демешко П.Д., Поляков С.Л., Степанович Е.А., Минич А.А.Krasny S.A., Demeshko P.D., Polyakov S.L., Stepanovich E.A., Minich A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://doklady.belnauka.by/jour/article/view/464

Работа посвящена результатам сравнительного исследования по изучению влияния адъювантной лучевой терапии на выживаемость до биохимического рецидива (БхР) у пациентов, перенесших радикальную простатэктомию (РПЭ) по поводу рака предстательной железы (РПЖ), в зависимости от пред- и послеоперационных факторов прогноза. Проведение адъювантной лучевой терапии после РПЭ в суммарной очаговой дозе 60 Гр у пациентов с местно-распространенным РПЖ (pT3a-b) или локализованным процессом после нерадикально хирургического вмешательства (рТ2R1) и высокодифференцированной аденокарциномой (сумма Глисона 6 и менее) по данным послеоперационного морфологического исследования позволяет статистически значимо на 25,7 % повысить 5-летний показатель выживаемости до БхР (р = 0,047) по сравнению с наблюдением. 

The article presents the results of a comparative study of the effect of adjuvant radiotherapy on the survival to biochemical recurrence (BCR) in patients undergoing radical prostatectomy (RP) of prostate cancer (PCa) depending on preand post-operative prognosis factors. Adjuvant radiation therapy following prostatectomy in a total focal dose of 60 Gy in patients with locally advanced prostate cancer (pT3a-b) or the localized process with positive surgical margins (rT2R1) and highly differentiated adenocarcinoma (Gleason score equal to 6 or less) according to a postoperative morphological examination significantly increases a 5-year survival to BCR by 25.7 % (p = 0.047) compared to observation. 

рак предстательной железырадикальная простатэктомиябиохимический рецидивлучевая терапияprostate cancerradical prostatectomybiochemical relapseradiation therapyReferencesSecondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy / O. Yossepowitch [et al.] // Eur. Urol. – 2008. – Vol. 53, N 5. – P. 950–959. doi. org/10.1016/j.eururo.2007.10.008Yossepowitch O., Eggener S. E., Serio A. M., Carver B. S., Bianco F. J., Scardino P. T., Eastham J. A. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. European Urology, 2008, vol. 53, no. 5, pp. 950–959. doi.org/10.1016/j.eururo.2007.10.008Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium / A. W. Partin [et al.] // Urology. – 2001. – Vol. 58, N 6. – P. 843–848. doi.org/10.1016/s0090-4295(01)01441-8Partin A. W., Mangold L. A., Lamm D. M., Walsh P. C., Epstein J. I., Pearson J. D. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology, 2001, vol. 58, no. 6, pp. 843–848. doi.org/10.1016/ s0090-4295(01)01441-8Radical prostatectomy versus watchful waiting in early prostate cancer / A. Bill-Axelson [et al.] // N. Engl. J. Med. – 2005. – Vol. 352, N 19. – P. 1977–1984. doi.org/10.1056/nejmoa043739Bill-Axelson A., Holmberg L., Ruutu M., Häggman M., Andersson S.-O., Bratell S., Spångberg A., Busch C., Nordling S., Garmo H., Palmgren J., Adami H.-O., Norlén B. J., Johansson J.-E. Radical prostatectomy versus watchful waiting in early prostate cancer. New England Journal of Medicine, 2005, vol. 352, no. 19, pp. 1977–1984. doi.org/10.1056/nejmoa043739Radical prostatectomy versus watchful waiting in early prostate cancer / A. Bill-Axelson [et al.] // N. Engl. J. Med. – 2011. – Vol. 364, N 18. – P. 1708–1717. doi.org/10.1056/nejmoa1011967Bill-Axelson A., Holmberg L., Ruutu M., Garmo H., Stark J. R., Busch C., Nordling S., Häggman M., Andersson S.-O., Bratell S., Spångberg A., Palmgren J., Steineck G., Adami H.-O., Johansson J.-E. Radical prostatectomy versus watchful waiting in early prostate cancer. New England Journal of Medicine, 2011, vol. 364, no. 18, pp. 1708–1717. doi.org/10.1056/ nejmoa1011967Natural history of progression after PSA elevation following radical prostatectomy / C. R. Pound [et al.] // J.A.M.A. – 1999. – Vol. 281, N 17. – P. 1591–1597. doi.org/10.1001/jama.281.17.1591Pound C. R., Partin A. W., Eisenberger M. A., Chan D. W., Pearson J. D., Walsh P. C. Natural history of progression after PSA elevation following radical prostatectomy. J.A.M.A, 1999, vol. 281, no. 17, pp. 1591–1597. doi.org/10.1001/jama.281.17.1591Declining use of radiotherapy for adverse features after radical prostatectomy: results from the National cancer data base / H. M. Sineshaw [et al.] // Eur. Urol. – 2015. – Vol. 68, N 5. – P. 768–774. doi.org/10.1016/j.eururo.2015.04.003Sineshaw H. M., Gray P. J., Efstathiou J. A., Jemal A. Declining use of radiotherapy for adverse features after radical prostatectomy: results from the National cancer data base. European Urology, 2015, vol. 68, no. 5, pp. 768–774. doi. org/10.1016/j.eururo.2015.04.003Management of prostate-specific antigen relapse in prostate cancer: a European Consensus / L. Boccon-Gibod [et al.] // Int. J. Clin. Pract. – 2004. – Vol. 58, N 4. – P. 382–390. doi.org/10.1111/j.1368-5031.2004.00184.xBoccon-Gibod L., Djavan B., Hammerer P., Hoeltl W., Kattan M. W., Prayer-Galetti T., Teillac P., Tunn U. W. Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. International Journal of Clinical Practice, 2004, vol. 58, no. 4, pp. 382–390. doi.org/10.1111/j.1368-5031.2004.00184.xMoul, J. W. Prostate specific antigen only progression of prostate cancer / J. W. Moul // J. Urol. – 2000. – Vol. 163, N 6. – P. 1632–1642. doi.org/10.1016/s0022-5347(05)67511-8Moul J. W. Prostate specific antigen only progression of prostate cancer. The Journal of Urology, 2000, vol. 163, no. 6, pp. 1632–1642. doi.org/10.1016/s0022-5347(05)67511-810-Year outcomes aftermonitoring, surgery, or radiotherapy for localized prostate cancer / F. C. Hamdy [et al.] // N. Engl. J. Med. – 2016. – Vol. 375, N 15. – P. 1415–1424. doi.org/10.1056/nejmoa1606220Hamdy F. C., Donovan J. L., Lane J. A., Mason M., Metcalfe C., Holding P., Davis M., Peters T. J., Turner E. L., Martin R. M., Oxley J., Robinson M., Staffurth J., Walsh E., Bollina P., Catto J., Doble A., Doherty A., Gillatt D., Kockelbergh R., Kynaston H., Paul A., Powell P., Prescott S., Rosario D. J., Rowe E., Neal D. E. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. New England Journal of Medicine, 2016, vol. 375, no. 15, pp. 1415–1424. doi.org/10.1056/ nejmoa1606220The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary / J. K. Mullins [et al.] // J. Urol. – 2012. – Vol. 188, N 8. – P. 2219–2224. doi.org/10.1016/j.juro.2012.08.028Mullins J. K., Feng Z., Trock B. J., Epstein J. I., Walsh P. C., Loeb S. The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary. The Journal of Urology, 2012, vol. 188, no. 8, pp. 2219–2224. doi. org/10.1016/j.juro.2012.08.028The role of radiotherapy after radical prostatectomy in patients with prostate cancer / G. Gandaglia [et al.] // Curr. Oncol. Rep. – 2015. – Vol. 17, N 12. – P. 53. doi.org/10.1007/s11912-015-0478-5Gandaglia G., Cozzarini C., Mottrie A., Bossi A., Fossati N., Montorsi F., Briganti A. The role of radiotherapy after radical prostatectomy in patients with prostate cancer. Current Oncology Reports, 2015, vol. 17, no. 12, pp. 53. doi.org/10.1007/ s11912-015-0478-5Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) / M. Bolla [et al.] // Lancet. – 2012. – Vol. 380, N 9858. – P. 2018–2027. doi.org/10.1016/ s0140-6736(12)61253-7Bolla M., van Poppel H., Tombal B., Vekemans K., da Pozzo L., de Reijke T. M., Verbaeys A., Bosset J.-F., van Velthoven R., Colombel M., van de Beek C., Verhagen P., van den Bergh A., Sternberg C., Gasser T., van Tienhoven G., Scalliet P., Haustermans K., Collette L. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). The Lancet, 2012, vol. 380, no. 9858, pp. 2018–2027. doi.org/10.1016/s0140-6736(12)61253-7Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial / T. Wiegel [et al.] // Eur. Urol. – 2014. – Vol. 66, N 2. – P. 243–250. doi.org/10.1016/j.eururo.2014.03.011Wiegel T., Bartkowiak D., Bottke D., Bronner C., Steiner U., Siegmann A., Golz R., Störkel S., Willich N., Semjonow A., Stöckle M., Rübe C., Rebmann U., Kälble T., Feldmann H. J., Wirth M., Hofmann R., Engenhart-Cabillic R., Hinke A., Hinkelbein W., Miller K. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. European Urology, 2014, vol. 66, no. 2, pp. 243–250. doi.org/10.1016/j.eururo.2014.03.011Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases / A. W. Partin [et al.] // Urology. – 1994. – Vol. 43, N 5. – P. 649–659. doi.org/10.1016/0090-4295(94)90180-5Partin A. W., Pound C. R., Pearson J. D., Clemens J. Q., Landis P. K., Epstein J. I., Carter H. B., Walsh P. C. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology, 1994, vol. 43, no. 5, pp. 649–659. doi.org/10.1016/0090-4295(94)90180-5

The authors declare that there are no conflicts of interest present.